Apidra supply problems in the UK and in Finland (maybe in other countries, too)
Sanofi-Aventis has problems with their Apidra production.
In Finland pharmacies will not receive new shipments of Apidra insulin from mid-October.
Big warnings in the UK, too:
http://www.psnc.org.uk/news.php/1130/apidra_supply_issues
Hopefully the supply problems are solved by January 2012 or so. Let's see.
(In Finland doctors start to write rx:s for Humalog and NovoRapid(=Novolog), so we diabetic citizens still get rapid-acting insulin during the supply problems.
Googled more info. Spillage in factory in Frankfurt, Germany. It seems that the supply problem impacts mostly EU countries.
In Finland pharmacies will not receive new shipments of Apidra insulin from mid-October.
Big warnings in the UK, too:
http://www.psnc.org.uk/news.php/1130/apidra_supply_issues
Hopefully the supply problems are solved by January 2012 or so. Let's see.
(In Finland doctors start to write rx:s for Humalog and NovoRapid(=Novolog), so we diabetic citizens still get rapid-acting insulin during the supply problems.
Googled more info. Spillage in factory in Frankfurt, Germany. It seems that the supply problem impacts mostly EU countries.
Shortage of Apidra (insulin glulisine) cartridges
The European Medicines Agency is aware of a shortage of Apidra, a medicine for treating diabetes,
affecting the supply of Apidra 3 ml cartridges and Apidra prefilled disposable pens (OptiSet and
SoloStar) in several EU Member States. The Agency’s Committee for Medicinal Products for Human Use
(CHMP) has made several recommendations to manage the situation and ensure patients continue to
receive appropriate treatment during the temporary supply shortage.
What is Apidra?
Apidra is a solution for injection that contains the active substance insulin glulisine. It is used to treat
patients aged six years or over with diabetes, when they need insulin.
Apidra is supplied in vials, cartridges and prefilled disposable pens (called OptiSet and SoloStar).
Apidra is given by injection under the skin or by continuous infusion with an insulin pump. The vials are
used together with an insulin syringe to inject the medicine, or with an insulin pump. The cartridges
are used together with a pen device1 to inject the medicine. The prefilled pens are used alone to inject
the medicine.
Apidra is a rapid-acting insulin analogue (chemically modified insulin) that is used in combination with
intermediate- or long-acting insulins or insulin analogues. It may also be used in combination with
other (oral) medicines to treat diabetes.
What is the cause of the supply problem and how long will it last?
The company that markets Apidra, Sanofi-Aventis Deutschland GmbH, informed the Agency that an
accidental spillage occurred on 11 July 2011 at the plant where the medicine is manufactured in
Frankfurt, Germany. Manufacturing has been temporarily suspended while internal investigations are
taking place. This will result in a continued delay in the release of batches of Apidra cartridges onto the
EU market. The shortage affects Apidra cartridges and Apidra prefilled disposable pens, OptiSet and
SoloStar. It does not affect Apidra vials or any other Sanofi insulin product (Lantus and Insuman).
1 Cartridges are suitable for use with OptiPen, ClikSTAR, Tactipen or Autopen 24, and specific cartridges are suitable for use
with OptiClik.
Normal supply is expected to resume in early 2012. Supply shortages are expected in most EU Member
States until normal supply resumes.
What are the recommendations of the CHMP to cope with the shortage?
Apidra cartridges and prefilled disposable pens currently on the market are safe to use.
The Committee has agreed that the company should provide a letter to the healthcare professionals,
health authorities and wholesalers explaining the specific supply situation in their countries together
with recommendations to manage the situation. During the supply shortage, if cartridges or prefilled
pens are not available, the main recommendations are as follows taking account of national guidance
and the needs of individual patients:
•
Patients may be switched to an alternative rapid-acting insulin analogue – i.e. Humalog (insulin
lispro) or NovoRapid (insulin aspart) under the supervision of a healthcare professional and with
close monitoring of blood glucose levels.
•
Where rapid-acting insulin analogues are not available or not appropriate, patients may need to be
switched to regular (standard) short-acting human insulin such as Insuman, Humulin, Novolin or
equivalent. As these insulins have a slower onset and a longer duration of action than Apidra, this
must be done under the direct supervision of a healthcare professional with more frequent
monitoring of blood glucose levels and adjusted dose as required.
•
Patients for whom vials and syringes are an acceptable alternative to a pen device may be
switched to Apidra vials and syringes if available. No dose adjustment is required.
The company is providing a program of support for healthcare professionals and patients during the
supply shortage, including a demonstration video and educational materials on switching to using vials
and syringes, rapid-acting insulin analogues or regular short-acting human insulin. The company will
also provide a national helpline for patients and healthcare professionals in the countries concerned.
The Committee is working closely with Sanofi-Aventis Deutschland GmbH to ensure that normal supply
is resumed as soon as possible in the interest of patients.
The current European public assessment report for Apidra can be found on the Agency’s website:
ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Replies to This Discussion
-
Permalink Reply by Trudy on -
Hi Anna. I use Apidra for MDI and part-time on the MM522. I keep my Apidra vial in the fridge between all uses, including MDI, and it lasts for 24 days all year. I found out early that it's was more temperature sensitive than other types of inslin. I trust my pharmacy to keep it refrigerated, but I have to wonder if there are storage problems or traveling problems before the Apidra gets to my pharmacy that contributes to causing its shorter life.
-
Permalink Reply by Kelly WPA on -
Trudy, I have wondered the same thing about the traveling thoughts. I never had a problem until last Dec and I started Apidra in 2008. I switched from pens to vials last June when I started the pump. I also had to change pharmacies. The vial problem started in Dec and it took me awhile to even figure that out because I had been using it for a week and it was fine. I always kept my vials in the fridge and in Dec, I wasn't even letting them sit out to warm up before filling up the cartridge. This summer, I started having a problem with my pens. Those I keep out of the fridge once I start using them and they were dying after about 7 days. I keep my place on the cold site with AC running constantly and the insulin rarely goes outside. I had to get the insulin for my pump at a different pharmacy & the two are about 40 miles apart.
When I originally had the problem, I was getting a lot of searches to my blog with "Apidra problems." I know that could mean anything, but when I Googled the same term, I came up with another blogger up in NY (I am in Western PA) that was having the same problem.
Not sure what is causing it, but it is very hit & miss and very annoying when you end up throwing a lot of insulin away.
-
Permalink Reply by Gary on -
Sanfi Aventis is a joke. They bought the rights to Curedm's (Pancreate which could have turned out to be a regeneration therapy for type 1's ) almost 2 years ago and they haven't done jack shit with it. A complete insult to the diabetes community.
-
Permalink Reply by MossDog on -
Gary- Can you say for a certainty what Sanofi has done with Pancreate? Could they have had a team of scientist conlude that in it's current form it is not feasible but with slight modifications it could work with them working on the modifications now? How can you know for sure?
(Pancreate which could have turned out to be a regeneration therapy for type 1's )
I bolded the key word in you statement. The simple fact of the matter is could does not always mean a company should continue to invest in a solutiuon to a problem no matter how much we all hate this disease and wish it were gone.
I simply don't buy the argument that all the insulin manufactuer's want to stop promising curative research. After all, once they develop it they get to set the price as there would be no competition. Seems like a money maker to me. Just because you cure a person with type 1 dosen't mean there won't be another who will be diagnosed in short order. Also, who is to say these therapies won't be needed on a consistent basis?
I am by no means a supporter of big pharma. I think patients, in particualr USA patients, have been getting the shaft from these companies. But making statements of fact when you can't know exactly what they are or are not doing is unproductive.
-
Permalink Reply by karri on -
So wow. My son uses Apidra in pump. First reading this I thought that it doesnt concern us as vials are not affected. Then later on I realised they dont sell vials for pump-users in Finland, only cartridges (which we use).
-
Permalink Reply by Manny Hernandez on -
Today we received information from Sanofi-Aventis that they have made available this offer to patients in the US:
http://www.apidra.com/copaycard/default.aspx
"From now until April 30, 2012, Apidra® vials are free for patients with commercial insurance..."
-
Permalink Reply by Kelly WPA on
-
Jake, you are right, it is not valid in MA. I can't get it either because I have a Medicare plan - my plan pays more than most plans do but I get screwed too.
- ‹ Previous
- 1
- 2
- Next ›
Advertisement
REsources
Groups
From the Diabetes Hands Foundation blog...
Congratulations Diabetes Advocates Scholarship Recipients!
The Diabetes Hands Foundation and Diabetes Advocates Program is proud to announce and congratulate the members of DA who were granted scholarships to attend diabetes conferences in 2013! Thanks to a generous grant from Novo Nordisk, in 2013 we were …Continue Reading
La Familia de EsTuDiabetes Sigue Creciendo
El Centro Nacional de Prevención de Enfermedades Crónicas y Promoción de la Salud en el Estados Unidos encontró que a partir de 2002-2009, el 11,8% de los hispanos mayores de 20 años, que viven en los EU, viven con diabetes …Continue Reading
TuDiabetes Team
DHF STAFF
 Manny Hernandez(Co-Founder, Editor, has LADA)
|
DHF VOLUNTEERS
Lead Administrator
 Bradford (has type 1) |
Administrators
 Lorraine (mother of type 1) |
 Marie B (has type 1) |
|
|
|
|
|
|
LIKE us on Facebook
Spread the word
This site complies with the HONcode standard for trustworthy health information: verify here.
© 2013 A community of people touched by diabetes, run by the Diabetes Hands Foundation.
